Hemophilia B – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Hemophilia B

Hemophilia B – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Hemophilia B (also called Christmas Disease) is a rare hereditary bleeding disorder caused by the insufficient level of blood protein called coagulation factor IX. According to Thelansis disease modeling data, about 30% of new cases of hemophilia B is caused by mutation in the F9 gene, responsible for the formation of factor IX protein. This mutation is due to X-linked recessive disorder which alter genes on the X chromosome.

There is another unusaul form of factor IX deficiency called Hemophilia B Leyden approximately 3% of the hemophilia B cases. Depending upon the particular hemophilia B Leyden mutation present, there are undetectable levels of factor IX present early in life that increase over time. By midlife, these patients have factor IX levels at the low end of the normal range.

According to Thelansis, Hemophilia B affects 1 in 500 male births in the U.S., and approximately 100 babies are born with hemophilia B each year. Approximately 400,000 people worldwide are living with hemophilia, and about 24,000 are living with it in the United States alone.

Classification- Hemophilia B is classified as mild, moderate or severe based upon the activity level of factor IX. In mild cases, bleeding symptoms may occur only after surgery, injury or a dental procedure. In some moderate and most severe cases, bleeding symptoms may occur after a minor injury or spontaneously, meaning without an identifiable cause.

KOLs insights of Hemophilia B across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Competitive landscape of Hemophilia B includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Hemophilia B Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Hemophilia B – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S.No        Asset        Company                                Stage

1        rFIXFc        Bioverativ Therapeutics Inc.                Phase 1

2        Tranacogene Dezaparvovec (AMT-061)         UniQure  Phase 3

3        AskBio009        Baxalta now part of Shire        Phase 2

4        FLT180a        Freeline Therapeutics Phase 3

5        rIX-FP        CSL Behring                Phase 3

6        IB1001        Aptevo BioTherapeutics                Phase 3                

7        BeneFIX         Grifols Biologicals, LLC Phase 2

8        PF-06838435/ fidanacogene elaparvovec        Pfizer                Phase 3

9        MarzAA        Catalyst Biosciences Phase 3

10        APVO101        Medexus Pharma, Inc.  Phase 3

11        IB1001        Cangene Corporation Phase 3

12        nonacog beta pegol        Novo Nordisk A/S                Phase 3

13        Coagulation Factor VIIa (Recombinant)        rEVO Biologics                Phase 3

14        Coagulation FVIIa (Recombinant)        LFB USA, Inc.                Phase 3

15        SerpinPC        ApcinteX Ltd                Phase 2

16        MOD-5014         OPKO Health, Inc. Phase 2

17        BAY1093884        Bayer                Phase 1

18        ALN-AT3SC        Alnylam Pharmaceuticals Phase 1